ERBB2 and non-small cell lung carcinoma: Trastuzumab deruxtecan (T-DXd), a novel antibody-drug conjugate (ADC) targeting HER2, has received FDA approval for treating HER2-mutated, unresectable, or metastatic NSCLC in adults following systemic therapy.